Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 3/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730915 | 0.91 | JAK2 (0.38) | CSNK1ECSNK1DKCNK3MEN1KMT2A | |
| SCHEMBL16700752 | 0.90 | CSNK1E (0.45) | CSNK1ECSNK1DADORA1ADORA2AKCNK3 | |
| SCHEMBL16700782 | 0.90 | LMNA (0.35) | CSNK1ECSNK1DKCNK3LMNAALDH1A1 | |
| SCHEMBL16700100 | 0.83 | CSNK1E (0.43) | CSNK1ECSNK1DUSP30BTK | |
| SCHEMBL16711424 | 0.82 | CSNK1E (0.44) | CSNK1ECSNK1DKCNK3BTK | |
| SCHEMBL16709012 | 0.81 | SMN1; SMN2 (0.40) | KCNK3MEN1KMT2AUSP30 | |
| SCHEMBL16699593 | 0.80 | GRM5 (0.33) | USP30CNR2 | |
| SCHEMBL16728817 | 0.80 | JAK2 (0.40) | CSNK1ECSNK1DKCNK3USP30LMNA | |
| SCHEMBL16699030 | 0.80 | CSNK1E (0.42) | CSNK1ECSNK1DKCNK3 | |
| SCHEMBL16711428 | 0.74 | CSNK1E (0.42) | CSNK1ECSNK1DBTKCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068785-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3068784-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3068785-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015073763-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | CSNK1E 1/4885CSNK1D 7/4885ADORA1 3797/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | CSNK1E 1/4885CSNK1D 7/4885ADORA1 3797/4885 |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | CSNK1E 2/4885CSNK1D 6/4885ADORA1 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.